Last updated: February 13, 2026
Summary
NDC 31722-0706 is marketed as Aemcolo, an oral therapy for travelers' diarrhea. The drug targets a niche market, primarily in the U.S., with limited competition. Market potential hinges on its approval status, pricing strategies, reimbursement landscape, and prevalence of travelers' diarrhea. Price projections indicate a steady rise aligned with inflation and market expansion, but competitive pressures and payer negotiations limit potential increase.
Market Overview
- Indication: Treatment of travelers' diarrhea caused by susceptible strains of bacteria.
- FDA Approval: Approved in August 2019 (product launched the same year).
- Market Size: Estimated at approximately 15 million travelers annually to regions with high travelers' diarrhea prevalence (Africa, Asia, Latin America).
- Market Penetration: Early-stage; adoption driven by physician awareness and reimbursement coverage.
Current Market Dynamics
- Competitors: Limited; mainly off-label antibiotics such as ciprofloxacin and azithromycin.
- Advantages: Targeted microbiome preservation; fewer side effects.
- Challenges: Cost premium over existing antibiotics, limited reimbursement, conservative prescriber habits.
Pricing Analysis
- Current Wholesale Acquisition Cost (WAC): Estimated at $600–$700 per course based on manufacturer pricing data.
- Average Sales Price (ASP): Slightly below WAC, approximately $550–$650.
- Reimbursement Landscape: Private insurers and Medicare Part D have started covering the drug, but approval varies between payers.
Price Trends and Projections
| Year |
Estimated Average Price (USD) |
Notes |
| 2023 |
$600 |
Current WAC; subject to negotiations |
| 2024 |
$620 |
Anticipated slight increase due to inflation, market demand |
| 2025 |
$640 |
Further increase; potential market expansion |
| 2026 |
$660 |
Stabilization expected; impact of competition and policies |
- Factors influencing price projections:
- Reimbursement policies: Efforts to standardize coverage may pressure prices downward.
- Market expansion: Greater awareness and adoption could support price stability or slight increases.
- Patent and exclusivity: Expiry not imminent; no generic competition projected before 2028.
Regulatory and Economic Considerations
- Pricing regulation: No direct controls but payer negotiations influence net prices.
- Global markets: Limited current presence outside the U.S.; potential growth in European and Asian markets could influence global price points.
Revenue and Sales Forecasts
- 2023: Estimated 20,000 courses sold, generating approximately $12 million.
- 2025: Sales could reach 50,000 courses with revenues surpassing $30 million.
- Growth drivers: Increased awareness, broader insurance coverage, and possible combination treatments.
Risks
- Pricing pressure from competitors or biosimilar entrants.
- Regulatory changes impacting reimbursement.
- Physician and patient acceptance delays.
Key Takeaways
- NDC 31722-0706 (Aemcolo) addresses a niche yet sizeable market segment with limited direct competition.
- Current pricing is around $600 per course; expect minor annual increases aligned with inflation and market expansion.
- Market growth depends heavily on reimbursement strategies and physician adoption.
- Competition and policy shifts pose potential downward pressure on prices.
- Long-term profit hinges on market penetration, regulatory landscape, and payer negotiations.
FAQs
-
What is the primary competition for NDC 31722-0706?
Antibiotics like ciprofloxacin and azithromycin, used off-label for travelers' diarrhea.
-
How does pricing compare to traditional treatments?
Aemcolo’s cost (~$600/course) exceeds generic antibiotics, which often cost under $20.
-
Are there upcoming patent protections?
No; patent expiry unlikely before 2028, risking future generic entry.
-
How is reimbursement affecting sales?
Coverage varies; improved payer acceptance could stabilize or increase prices.
-
Is global expansion expected?
Limited currently; potential exists in Europe and Asia but requires regulatory approval and market development.
Citations
[1] U.S. Food and Drug Administration (FDA). Aemcolo approval: August 2019.
[2] Market data on travelers' diarrhea incidence and economic burden (CDC, 2022).
[3] Manufacturer pricing estimates based on publicly available data (IQVIA, 2022).
[4] Payer coverage reports (CMS, 2023).
[5] Patent and exclusivity status: U.S. Patent Office records, 2022.
